Objective To investigate effects of resovastain on the cardiac function of diabetic cardiomyopathy(DCM) in rats. Methods 50 Wistar rats 8 week old were randomly divided into three groups: the normal control group(n=８), the DCM group(n=21) and the DCM plus resovastain group(n=21). Four weeks later, the DCM animal model was established by intraperitoneal injection of streptozotocin (STZ)， which reached the standard was used for the following procedure; the DCM plus resovastatin group was intragastrically administered with resovastatin (20mg/kg/d). After 20 weeks, the role of resovastain in the process of DCM was observed by echocardiography, including left ventricular internal diameter at end-systole (LVIDs), left ventricular internal diastolic diameter (LVIDd), ejection fraction(EF,shortening fraction(FS), valvular regurgitation, Max E wave speed, Max A wave speed, ratio of E/A, E deceleration time(EDT′), isovolumic relaxation time (IVRT′) and aortic peak velocity(APV), and also by the detection of biochemical indices, including serum glucose, fasting insulin, triglyceride and cholesterol. Results ①One week after STZ injection, compared with the normal control group, the DCM group and DCM plus resovastatin group had a rise in levels of fasting blood glucose, triglyceride and cholesterol (P<0.01). At the end, compared with the normal control group, the body weight in other two groups significantly declined（P<0.01）and the fasting insulin level also declined (P<0.05), while levels of fasting blood glucose and triglyceride increased (P<0.01). The level of cholesterol in the DCM group increased (P<0.01), while there was no remarkable difference compared with the DCM plus resovastatin group (P>0.05).②The DCM group and DCM plus resovastatin group had a significant increase in LVIDd and LVIDs (P<0.01), and incidence of valvular regurgitation (P<0.05). E/A ratio and EF declined (P<0.01). Compared with the DCM group, LVIDs and LVIDd were ameliorated in the DCM plus resovastatin group (P<0.05), while the incidence of valvular regurgitation decreased (P<0.05) and the E/A ratio and EF increased (P<0.05). Conclusion Resovastatin can to a certain extent improve cardiac function and myocardial remodeling in DCM rats.
